RAGE blockade and hepatic microcirculation in experimental endotoxaemic liver failure

Area of Science:

• Immunology
• Hepatology
• Pharmacology

Background:

• The receptor for advanced glycation endproducts (RAGE) is implicated in sustained inflammatory pathway activation.
• RAGE is a potential therapeutic target for sepsis and endotoxaemic conditions.
• Endotoxaemic liver failure involves microcirculatory dysfunction and tissue injury.

Purpose of the Study:

• To investigate whether blocking RAGE in vivo can prevent microcirculatory dysfunction.
• To determine if RAGE blockade mitigates subsequent tissue injury in endotoxaemic liver failure.
• To evaluate the therapeutic potential of anti-RAGE antibodies in a murine model.

Main Methods:

• Intravital fluorescence microscopy was used to analyze hepatic microcirculation in mice subjected to galactosamine/lipopolysaccharide (G/L).
• Mice were treated with an anti-RAGE antibody (abRAGE) either before or after G/L exposure.
• Liver tissue and blood samples were analyzed for inflammatory markers, cell infiltration, apoptosis, necrosis, and RAGE signaling.

Main Results:

• abRAGE treatment significantly reduced sinusoidal perfusion failure, leucocyte stasis, rolling, adhesion, and tissue infiltration.
• Hepatocellular apoptosis and necrosis were markedly decreased following abRAGE administration.
• Plasma high-mobility group protein B1 levels and mitogen-activated protein kinase cascade activation were blunted by RAGE blockade.

Conclusions:

• RAGE plays a critical role in mediating liver damage during endotoxaemia.
• RAGE blockade, administered both pre- and post-insult, effectively attenuated hepatic microcirculatory deterioration and liver injury.
• Targeting RAGE represents a promising therapeutic strategy for managing endotoxaemia-related organ damage.